Please assess the completion status of the following clinical trial:

Trial Title: INFUSE Morphine Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females at least 18 years of age who are patients of San Diego Hospice \& Palliative Care or recruited through San Diego Hospice \& Palliative Care or the UCSD Center for Pain and Palliative Medicine.~2. During the treatment days of the study, on opioid therapy other than morphine that is equivalent to ≥ 60 mg oral morphine per day and without unacceptable toxicity.~3. Vital signs (BP, HR, RR) within normal range.~4. Adequate venous access in both upper extremities.~5. A negative pregnancy test (if female of child-bearing potential) within 7 days prior to first injection.~6. Life expectancy ≥ ten days.~7. Decision-making capacity.~8. Signed, written IRB-approved informed consent. -~Exclusion Criteria:~1. Known hypersensitivity or history of any toxicity to morphine.~2. Morphine within the 4 days prior to the first study medication injection or anticipated to be receiving morphine during any of the treatment days in this study.~3. Any contraindication to morphine.~4. Known hypersensitivity to naloxone.~5. Known allergy to hyaluronidase or any other ingredient in the formulation of HYLENEX.~6. Known allergy to bee or vespid venom.~7. Contraindication to IV heparin lock or known hypersensitivity to heparin.~8. Edema, infection, or any other lower extremity or pelvic disorder that might affect subcutaneous absorption from the thigh.~9. Hemoglobin \< 10 g/dL.~10. Presence of any other medical condition that would present an unacceptable safety risk to the patient.~11. Participation in a study of any investigational drug or device within 30 days of enrollment in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): IV Morphine
- 2 (Type: EXPERIMENTAL): SC Morphine with Hylenex
- 3 (Type: ACTIVE_COMPARATOR): SC Morphine with Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).